(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 June 2009 (04.06.2009)

PCT

(10) International Publication Number
WO 2009/068955 A3

(51) **International Patent Classification**:
C07D 487/04 (2006.01) ***A61P 35/00*** (2006.01)
A61K 31/519 (2006.01)

(21) **International Application Number**:
PCT/IB2008/003170

(22) **International Filing Date**:
18 November 2008 (18.11.2008)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
60/991,169 29 November 2007 (29.11.2007) US

(71) **Applicant** *(for all designated States except US)*: **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **COLLMAN, Benjamin, Micah** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, CT 06340 (US). **CUI, Jingrong, Jean** [US/US]; Pfizer Global Research & Development, 10555 Science Center Drive, San Diego, CA 92121 (US).

(74) **Agent**: **FULLER, Grover, F., Jr.**; Pfizer Inc., 150 East 42nd Street, New York, NY 10017 (US).


(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) **Title**: POLYMORPHS OF A C-MET/HGFR INHIBITOR

FIG. 1



(57) **Abstract**: This invention relates to polymorphs of 2-[4-(3-Quinolin-6-ylmethyl-3H- [1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.

WO 2009/068955 A3

ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:
27 May 2010